Minigastrin

DB19196InvestigationalProtein Based Therapies

Minigastrin is under investigation in clinical trial NCT06155994 (68ga-dota-mgs5 PET/CT in Patients With Advanced Neuroendocrine Tumours).

Mechanism
Curator reviewed
Also known as
21-34-gastrin · L-phenylalaninamide, l-leucyl-l-.alpha.-aspartyl-l-.alpha.-aspartyl-l-.alpha.-aspartyl-l-.alpha.-aspartyl-l-.alpha.-aspartyl-l-alanyl-l-tyrosylglycyl-l-tryptophyl-l-leucyl-l-.alpha.-aspartyl-

Resolves to

Compound
UNII262J9O2552CAS101212-63-9
Targets
P32239CCKBR

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Minigastrin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In